Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: February 4, 2023

Details for Patent: 8,158,601

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,158,601 protect, and when does it expire?

Patent 8,158,601 protects ONPATTRO and is included in one NDA.

This patent has sixty-eight patent family members in twenty-three countries.

Summary for Patent: 8,158,601
Title:Lipid formulation
Abstract: The invention features a cationic lipid of formula I, ##STR00001## an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
Inventor(s): Chen; Jianxin (Cambridge, MA), Ansell; Steven (Cambridge, MA), Akinc; Akin (Cambridge, MA), Dorkin; Joseph Robert (Cambridge, MA), Qin; Xiaojun (Cambridge, MA), Cantley; William (Cambridge, MA), Manoharan; Muthiah (Cambridge, MA), Rajeev; Kallanthottathil G. (Cambridge, MA), Narayanannair; Jayaprakash K. (Cambridge, MA), Jayaraman; Muthusamy (Cambridge, MA)
Assignee: Alnylam Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/813,448
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Delivery;

Drugs Protected by US Patent 8,158,601

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alnylam Pharms Inc ONPATTRO patisiran sodium SOLUTION;INTRAVENOUS 210922-001 Aug 10, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,158,601

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010259984 See Plans and Pricing
Australia 2017202702 See Plans and Pricing
Australia 2019204984 See Plans and Pricing
Australia 2021201228 See Plans and Pricing
Canada 2764609 See Plans and Pricing
Canada 3014827 See Plans and Pricing
China 102625696 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.